title: Treatment for children with severe aplastic anemia and sickle cell disease in low income countries in Latin America: a report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO): Part III.
abstract: Treatment of hematologic disorders in low-income countries (LIC) is difficult. This report summarizes treatment of sickle cell disease and aplastic anemia by pediatric hematologists from 15 LIC who participate in the Monza International School of Pediatric Hematology/Oncology (MISPHO). Patients with severe sickle cell disease were treated with low dose hydroxyurea, which safely reduced vaso-occlusive crises. Patients with severe aplastic anemia fared poorly due to lack of availability and high cost of anti-thymocyte globulin and cyclosporine and lack of access to stem cell transplantation. Appropriate therapy was most likely to occur in MISPHO centers with an active twinning program with a center in a high-income country.
authors.affiliation: International Outreach Program and Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA. Scott.howard@stjude.org
authors.forename: Scott C
authors.initials: SC
authors.lastname: Howard
authors.forename: Judy A
authors.initials: JA
authors.lastname: Wilimas
authors.forename: Andronica
authors.initials: A
authors.lastname: Flores
authors.forename: C
authors.initials: C
authors.lastname: Pacheco
authors.forename: Gladis
authors.initials: G
authors.lastname: de Reyes
authors.forename: Sergio
authors.initials: S
authors.lastname: Machin
authors.forename: Eva
authors.initials: E
authors.lastname: Svarch
authors.forename: Marta
authors.initials: M
authors.lastname: Navarrete
authors.forename: Rosa
authors.initials: R
authors.lastname: Nieves
authors.forename: Hilze
authors.initials: H
authors.lastname: Rodriguez
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Masera
mesh_terms: D000741:Anemia, Aplastic / Q000628:therapy*; D000755:Anemia, Sickle Cell / Q000188:drug therapy*; D000961:Antilymphocyte Serum / Q000191:economics / Q000627:therapeutic use; D002648:Child; D016572:Cyclosporine / Q000191:economics / Q000627:therapeutic use; D003906:Developing Countries; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D007391:International Cooperation; D007843:Latin America
chemical_list: D000961:Antilymphocyte Serum; D016572:Cyclosporine; D006918:Hydroxyurea